Comparative Pharmacology
Head-to-head clinical analysis: ASMANEX HFA versus SYNALAR HP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASMANEX HFA versus SYNALAR HP.
ASMANEX HFA vs SYNALAR-HP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mometasone furoate is a corticosteroid that exerts anti-inflammatory effects by inhibiting multiple inflammatory cell types and mediators, including eosinophils, mast cells, macrophages, and lymphocytes, and reducing the release of pro-inflammatory cytokines and chemokines.
Corticosteroid that binds to glucocorticoid receptors, altering gene expression to inhibit inflammatory mediators (e.g., prostaglandins, leukotrienes) and suppress immune cell activity.
2 inhalations (100 mcg each) twice daily orally, maximum 400 mcg/day.
Apply a thin film to the affected area once or twice daily for up to 2 weeks, using the lowest effective dose. Not for use under occlusive dressings or on large areas.
None Documented
None Documented
The terminal elimination half-life of mometasone furoate following inhalation is approximately 25 hours (range 15–40 hours), reflecting slow absorption from the lungs and prolonged systemic clearance.
Terminal half-life: 2-3 hours (topical) due to rapid clearance; systemic half-life: 1-2 hours
Following oral inhalation, the absorbed fraction of mometasone furoate is extensively metabolized in the liver. Excretion is primarily via feces (approximately 74%) and urine (approximately 8%) as metabolites. Biliary excretion contributes to fecal elimination.
Renal: 90% as metabolites; biliary/fecal: minimal (<5%)
Category C
Category C
Corticosteroid, Inhaled
Corticosteroid